The Association of Peripheral Blood Immunoinflammatory Markers with PE and Adverse Outcomes in Preeclampsia: A Retrospective Study

外周血免疫炎症标志物与先兆子痫及不良结局的相关性:一项回顾性研究

阅读:1

Abstract

BACKGROUND: Preeclampsia (PE) is a syndrome exclusive to pregnancy, presenting substantial risks to maternal and fetal health. Systemic immune-inflammatory response is a prominent feature of PE. METHODS: A retrospective study was conducted involving 749 pregnant women in Guangzhou, China from September 2018 to September 2024. Three hundred and seventy participants were diagnosed with PE, 166 of which had adverse pregnancy outcomes (APOs). Immuno-inflammatory markers expressed in peripheral blood were evaluated during the second-trimester. APOs included postpartum haemorrhage (PPH), premature rupture of membranes (PROM), placental abruption, fetal growth restriction, neonatal intensive care unit (NICU) transfer, and fetal distress. The relationship between immune-inflammatory markers and PE and APOs was analyzed. RESULTS: Women with PE were at higher risk of APOs and had higher levels of neutrophil-to-lymphocyte ratio (NLR), systemic immunoinflammatory index (SII) and systemic inflammatory response index (SIRI). The AUC values for NLR, SII, and SIRI with PE were 0.594, 0.649, and 0.646 (P < 0.001), with cut-off values of 4.389, 994.863, and 2.406, respectively. For APOs in PE, the AUC values were 0.632, 0.627 and 0.669, with cut-off values of 4.959, 1070.408 and 3.346, respectively. Analysis indicated higher SII levels with increased incidences of fetal growth restriction, NICU transfer and fetal distress, and SIRI levels with NICU transfer and fetal distress (P < 0.05). CONCLUSION: Elevated levels of immune-inflammatory markers including NLR, SII, and SIRI are associated with PE and APOs. Our findings underscored the different optimal cut-off values of immune-inflammatory markers in the pregnant women between PE and the APOs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。